GLP-1 receptor agonist as adjuvant therapy in Type 1 diabetes: No apparent benefit for Beta-Cell function or glycemia
Side effect comparison The side effect comparison between semaglutide and tirzepatide shows that GI side effects are a class effect of GLP-1 agonism
Nbia Com cada vez mais opes surgindo no mercado, os medicamentos base de GLP-1 tm sido muito falados e usados por pessoas que buscam controle do diabetes tipo 2 e/ou reduo de peso
More serious concerns include potential hair loss , muscle pain , and pancreatitis risk, though serious side effects are relatively rare
Clear your schedule if possible
However, the primary difference lies in receptor activity: * Semaglutide: Primarily targets GLP-1 * Tirzepatide: Dual agonist targeting GLP-1 and GIP * Retatrutide: Triple agonist targeting GLP-1, GIP, and glucagon This expanded mechanism may offer researchers broader opportunities to study integrated metabolic pathways